ZBD(SH:603567) Shang Hai Zheng Quan Bao·2025-10-14 19:30Core Viewpoint - The announcement details the reduction of shareholding by a major shareholder, Bozhou Junze Fanglong Equity Investment Center, from over 5% to below 5% in Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd, indicating a planned share reduction without triggering a mandatory takeover bid [2][8]. Group 1: Shareholder Information - The major shareholder, Bozhou Junze, has reduced its holdings to 46,987,400 shares, representing a decrease to 4.9934% of the total shares, thus no longer qualifying as a major shareholder [2][5]. - The reduction is part of a previously disclosed plan to sell up to 28,229,895 shares, or 3% of the total share capital, through centralized bidding or block trading from September 10, 2025, to December 9, 2025 [2][14]. Group 2: Shareholding Changes - The company has conducted several share buybacks, which have affected the total share capital and the percentage of shares held by Bozhou Junze. The total share capital decreased from 941,963,592 shares to 940,996,515 shares due to the buybacks [4][16]. - Following the buybacks, Bozhou Junze's shareholding percentage increased passively to 5.9239% after the first buyback, and subsequently to 5.9291% after the last buyback before the reduction [4][16]. Group 3: Compliance and Future Plans - The share reduction complies with relevant laws and regulations, and the company will monitor the progress of the share reduction closely [8][23]. - Bozhou Junze has indicated that it may consider further increases or decreases in its holdings within the next 12 months, depending on market conditions [14][15].